share_log

復宏漢霖(02696.HK)旗下HLX22美國臨床試驗申請獲批

AASTOCKS ·  May 6 16:59

復宏漢霖(02696.HK)公布,自主研發的HLX22(抗人表皮生長因子受體-2(HER2)人源化單克隆抗體注射液)聯合曲妥珠單抗,及化療一線治療HER2陽性晚期胃癌的3期臨床試驗申請,獲美國食品藥品管理局批准。

復宏漢霖透露,相關藥物潛在適應症包括胃癌和乳腺癌等實體瘤,並已於中國境內完成用於HER2過表達晚期實體瘤治療的1期臨床研究。另外,於全球範圍內尚無同類聯合用藥治療方案獲批用於治療胃癌。(js/cy)

~

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment